Based on the Corcept Therapeutics Incorporated stock forecast from 3 analysts, the average analyst target price for Corcept Therapeutics Incorporated is USD 58.40 over the next 12 months. Corcept Therapeutics Incorporated’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Corcept Therapeutics Incorporated is Slightly Bullish , which is based on 9 positive signals and 4 negative signals. At the last closing, Corcept Therapeutics Incorporated’s stock price was USD 51.40. Corcept Therapeutics Incorporated’s stock price has changed by -7.22% over the past week, -10.67% over the past month and +56.90% over the last year.
No recent analyst target price found for Corcept Therapeutics Incorporated
No recent average analyst rating found for Corcept Therapeutics Incorporated
Company Overview Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California. Read Less
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hyp...Read More
Frequently Asked Questions About Corcept Therapeutics Incorporated (CORT) Stock
Based on ratings from 3 analysts Corcept Therapeutics Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on CORT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for CORT is USD 58.40 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 35.
CORT stock's Price/Earning ratio is 48.24.
Our analysis grades CORT stock's Price / Earning ratio at F. This means that CORT stock's Price/Earning ratio is above 83% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CORT may be a overvalued for its sector.
The last closing price of CORT's stock was USD 51.40.
The most recent market capitalization for CORT is USD 6.37B.
Based on targets from 3 analysts, the average taret price for CORT is projected at USD 58.40 over the next 12 months.
This means that CORT's stock price may go up by +13.62% over the next 12 months.
We can't find any ETFs which contains Corcept Therapeutics Incorporated's stock.
As per our most recent records Corcept Therapeutics Incorporated has 352 Employees.
Corcept Therapeutics Incorporated's registered address is 149 Commonwealth Drive, Menlo Park, CA, United States, 94025.
You can get more information about it from Corcept Therapeutics Incorporated's website at https://www.corcept.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Corcept Therapeutics Incorporated (CORT) Stock
Based on ratings from 3 analysts Corcept Therapeutics Incorporated's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on CORT's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for CORT is USD 58.40 over the next 12 months. The maximum analyst target price is USD 76 while the minimum anlayst target price is USD 35.
CORT stock's Price/Earning ratio is 48.24.
Our analysis grades CORT stock's Price / Earning ratio at F. This means that CORT stock's Price/Earning ratio is above 83% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CORT may be a overvalued for its sector.
The last closing price of CORT's stock was USD 51.40.
The most recent market capitalization for CORT is USD 6.37B.
Based on targets from 3 analysts, the average taret price for CORT is projected at USD 58.40 over the next 12 months.
This means that CORT's stock price may go up by +13.62% over the next 12 months.
We can't find any ETFs which contains Corcept Therapeutics Incorporated's stock.
As per our most recent records Corcept Therapeutics Incorporated has 352 Employees.
Corcept Therapeutics Incorporated's registered address is 149 Commonwealth Drive, Menlo Park, CA, United States, 94025.
You can get more information about it from Corcept Therapeutics Incorporated's website at https://www.corcept.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CORT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
